FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Merck (MRK) said the FDA approved KEYTRUDA (pembrolizumab) and KEYTRUDA QLEx (pembrolizumab + berahyaluronidase alfa-pmph) in combination with Padcev (enfortumab vedotin-ejfv) for adults with muscle-invasive bladder cancer as neoadjuvant therapy, then continued after cystectomy as adjuvant treatment. This approval is a meaningful positive catalyst for Merck’s oncology franchise and supports incremental treatment adoption post-surgery.

Analysis

This is more durable franchise maintenance than a near-term EPS step-up. The approval helps MRK extend Keytruda’s relevance into a high-acuity perioperative setting where standards of care are sticky, which matters more for terminal-value support and post-LOE positioning than for the next quarter’s sales line. The second-order beneficiary is PFE via the Padcev economics; this reinforces the ADC+IO template and raises the bar for competing bladder regimens that lack comparable combo momentum.

The market should be careful not to extrapolate a fast revenue ramp. Adoption in neoadjuvant/adjuvant oncology is gated by surgical pathways, toxicity management, and reimbursement, so the financial inflection is likely months, not days. If uptake is real, it should show up first in management commentary and then in model revisions; if not, this reads as label breadth without meaningful sell-through. The main falsifier is muted quarterly commentary on bladder contribution despite the new label.

Contrarianly, consensus may be underestimating how much this helps MRK’s durability narrative and overestimating the immediate commercial impact. The real asset is not this indication’s size but the precedent it sets for keeping PD-1 relevant in combination regimens as the franchise ages. Conversely, if investors already expected broad perioperative adoption, the stock reaction could fade quickly and become a better relative-value than outright-long setup.

Key Decisions for Investors

• Long MRK on any post-event pullback over the next 1-5 trading days; target 1-3 month relative outperformance as Street models modest terminal-value extension rather than near-term EPS upside.
• Prefer a relative-value pair: long MRK / short BMY for the next 1-3 months, betting that oncology-durability sentiment accrues to MRK while BMY remains more exposed to patent-cliff skepticism; stop if MRK fails to hold outperformance after the first earnings commentary.
• Watch PFE as the secondary beneficiary; if the market underprices Padcev economics, long PFE versus XBI on a 1-3 month horizon offers cleaner beta-adjusted exposure to the same bladder-cancer adoption theme.
• Avoid paying up for short-dated MRK calls; the commercial catalyst is too slow for weekly gamma. If using options, favor 3-6 month call spreads only after confirming the first management update on uptake.